Trending
November 1, 2024 Coya Therapeutics Promotes Arun Swaminathan, Ph.D. to Chief Executive OfficerOctober 31, 2024 Elektrofi Closes $112.25 Million Series C FinancingOctober 31, 2024 MiNK Therapeutics Appoints Dr. Robert Kadlec to Board of DirectorsOctober 31, 2024 Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific OfficerOctober 30, 2024 Orthobond Appoints George Landau as EVP, Business Development and Commercialization
Featured
November 1, 2024
Coya Therapeutics Promotes Arun Swaminathan, Ph.D. to Chief Executive Officer
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company developing... Read more »
October 31, 2024
Elektrofi Closes $112.25 Million Series C Financing
Elektrofi, Inc., a biopharmaceutical delivery technology company focused on improving the patient experience and... Read more »
October 31, 2024
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board of Directors
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering... Read more »
November 1, 2024
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
October 31, 2024
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
October 31, 2024
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
October 31, 2024
Pulse Biosciences Appoints David Kenigsberg, M.D. As Chief Medical Officer Of Electrophysiology
